Day: May 4, 2022

– Achieved $6.9 Million in Total Revenue in the First Quarter of 2022, Including $5.5 Million in Net Revenue from Sales of COSELA™ (trilaciclib) – – Fully Deployed G1’s COSELA Sales Team as of Mid-February 2022 – – Confirmed Expected Timelines for Initial Results of Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib – – Presented Real-World Data Showing Impact of Trilaciclib on Hospitalizations and Burden of Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Undergoing Chemotherapy – – Management to Host Webcast and Conference Call today at 8:30 AM ET – RESEARCH TRIANGLE PARK, N.C., May 04, 2022 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial...

CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in fireside chats during the following May investor conferences:BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022, at 2:00 p.m. PT in Las Vegas; and, 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022, at 2:35 p.m. ET in NYC.Live webcasts will be available in the investor section of the company’s website at www.beamtx.com, and will be archived for 60 days following the presentation. About Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform...

CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) — Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the following May investor conferences:BofA Securities 2022 Healthcare Conference (formal presentation) on Wednesday, May 11, 2022, at 2:40 p.m. PT in Las Vegas; and, 2022 RBC Capital Markets Global Healthcare Conference (fireside chat) on Wednesday, May 18, 2022, at 1:35 p.m. ET in NYC.Live webcasts will be available in the investor section of the company’s website at www.vervetx.com and will be archived for 60 days following the presentations. About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a genetic medicines...

DALLAS, May 04, 2022 (GLOBE NEWSWIRE) — Blucora, Inc. (NASDAQ: BCOR), a leading provider of technology-enabled, tax focused financial solutions, today announced financial results for the first quarter ended March 31, 2022. First Quarter Highlights and Recent DevelopmentsGrew total revenue over 10% year over year to $307.6 million in Q1 2022. TaxAct gained 19bp of market share during the tax season – delivering on our promise at Investor Day. Avantax delivered net positive flows for the quarter, first time since Q1 2020. Ended the first quarter with total client assets of $86.1 billion, growing percent of advisory assets to 47.5%. Advisory assets at the end of the first quarter were $40.9 billion, with $1.2 billion growth in net new advisory assets, the highest ever for the Company. Expectation of double-digit top line growth...

EEZY PLC — INVESTOR NEWS — 4 MAY 2022 AT 12:30 Eezy Plc: Invitation to briefing on the Q1/2022 interim report Eezy Plc will publish the Interim report for 1-3/2022 on Tuesday 10 May 2022 approx. at 8.00. A Finnish-language webcast for investors, analysts and media will be heldon 10 May 2022 at 13.00 (Finnish time) athttps://eezy.videosync.fi/2022-q1    The webcast will be hosted by CEO Sami Asikainen and CFO Hannu Nyman. During the presentation, there will be an opportunity to ask questions via chat. A recording of the webcast will be later available at the company’s website.Further information: Hannu NymanCFOEezy Plchannu.nyman@eezy.fitel. +358 (0)50 306 9913

SEL to utilize Atotech’s Uniplate® equipment at SEL’s new PCB manufacturing facility in Idaho, USA Atotech products help SEL to build highly automated and environmentally sound PCB-manufacturing operationBERLIN, May 04, 2022 (GLOBE NEWSWIRE) — Atotech, a leading specialty chemicals technology company and a market leader in advanced electroplating solutions, and Schweitzer Engineering Laboratories (“SEL”), an industry leader in the design and manufacture of digital products and systems that protect, control, and automate electric power systems, today announced that they will partner at SEL’s state-of-the-art manufacturing facility under construction in Idaho, USA. SEL will utilize Atotech’s innovative Uniplate® equipment technology in their new 162,000 square-foot facility that will serve as home for SEL’s printed circuit board...

  Foundation S: Sanofi’s new philanthropic spearhead Paris, May 4, 2022. Sanofi today launches Foundation S – The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partnerships and collective action, Foundation S will focus on three critical areas: childhood cancer, the health of communities most vulnerable to the effects of climate change and pollution, and access to lifesaving medicines and vaccines. Serge WeinbergChairman of the Board of Directors, Sanofi and President, Foundation S“As a global healthcare company, we must take part in tackling some of the challenges our society faces. We are proud of what the Sanofi Espoir Foundation has achieved this past decade and the legacy it leaves. The world changes at an incredible pace and numerous new systemic challenges...